+43-123-13-985|info@ces.b2sg.org

The Cancer Epigenetics Society officially appoints Dr. Keith Robertson, Officer at the Cancer Epigenetics Society and Professor of Molecular Pharmacology & Experimental Therapeutics at Mayo Clinic, Rochester (MN, USA), Vice-President of the Cancer Epigenetics Society. Keith earned his Bachelor’s degree from Cornell University, and his PhD from Johns Hopkins University. He next did his Postdoctoral training with Dr. Peter Jones at the University of Southern California, and with Dr. Alan Wolffe at the National Institutes of Health (NIH). His first faculty position was within the intramural program at the NIH, followed by faculty positions at University of Florida, and the Mayo Clinic. Keith also served as President of the Epigenetics Society from 2005 to 2007, has published over 90 papers in cancer epigenetics, and his laboratory has been continuously funded by the NIH since 2000. His laboratory focuses on basic and translational research related to determining how epigenetic marks, especially DNA methylation and hydroxymethylation, are established and maintained in normal cells, and how these marks become disrupted and lead to common human diseases such as diabetes, cardiovascular disease, neurological disorders, and cancer. The Cancer Epigenetics Society looks forward to Dr. Keith Robertson’s leadership in furthering the Society’s mission to harness the power of epigenetics to better manage and curtail, if not cure cancer. Dr. Robertson is also Editor of the Cancer Epigenetics journal series .

2017-05-19T11:28:43+00:00